Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
DOCETAXEL 0-WATER
Krka d.d., Novo mesto Smarjeska cesta 6 8501 NOVO MESTO (SLOVENIË)
L01CD02
DOCETAXEL 0-WATER
Concentraat voor oplossing voor infusie
CITROENZUUR 0-WATER (E 330) ; ETHANOL 395 mg/ml ; POLYSORBAAT 80 (E 433) ; STIKSTOF (HEAD SPACE) (E 941),
Parenteraal
Docetaxel
Hulpstoffen: CITROENZUUR 0-WATER (E 330); ETHANOL 395 mg/ml; POLYSORBAAT 80 (E 433); STIKSTOF (HEAD SPACE) (E 941);
2013-02-27
1.3.1 Docetaxel SPC, Labeling and Package Leaflet NL SmPCPIL160906_3 25.11.2020 – Updated: 04.12.2020 Page 54 of 62 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TOLNEXA 20 MG/ML, CONCENTRAAT VOOR OPLOSSING VOOR INFUSIE 20 mg/1 ml concentrate for solution for infusion 80 mg/4 ml concentrate for solution for infusion 160 mg/8 ml concentrate for solution for infusion docetaxel READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Tolnexa is and what it is used for 2. What you need to know before you use Tolnexa 3. How to use Tolnexa 4. Possible side effects 5. How to store Tolnexa 6. Contents of the pack and other information 1. WHAT TOLNEXA IS AND WHAT IT IS USED FOR The name of this medicine is Tolnexa. Its common name is docetaxel. Docetaxel is a substance derived from the needles of yew trees. Docetaxel belongs to the group of anti-cancer medicines called taxoids. Tolnexa has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer: - For the treatment of advanced breast cancer, Tolnexa could be administered either alone or in combination with doxorubicin, or trastuzumab, or capecitabine. - For the treatment of early breast cancer with or without lymph node involvement, Tolnexa could be administered in combination with doxorubicin and cyclophosphamide. - For the treatment of lung cancer, Tolnexa could be administered either alone or in combination with cisplatin. - For the treatment of prostate cancer, Tolnexa is administered in combination with prednisone or prednisolone. - For the treatment of metastatic gastric cancer, Tolnexa is a Lees het volledige document
1.3.1 Docetaxel SPC, Labeling and Package Leaflet NL SmPCPIL160906_3 25.11.2020 – Updated: 04.12.2020 Page 2 of 62 1. NAME OF THE MEDICINAL PRODUCT Tolnexa 20 mg/ml, concentraat voor oplossing voor infusie 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate for solution for infusion contains 20 mg docetaxel. One vial of 1 ml of concentrate for solution for infusion contains 20 mg docetaxel. One vial of 4 ml of concentrate for solution for infusion contains 80 mg docetaxel. One vial of 8 ml of concentrate for solution for infusion contains 160 mg docetaxel. Excipient with known effect: One vial of 1 ml of concentrate for solution for infusion contains 0.5 ml anhydrous ethanol (395 mg). One vial of 4 ml of concentrate for solution for infusion contains 2 ml anhydrous ethanol (1580 mg). One vial of 8 ml of concentrate for solution for infusion contains 4 ml anhydrous ethanol (3160 mg). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate) The concentrate is a clear pale yellow to brownish-yellow solution. _ _ _ _ 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Breast cancer Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: - operable node-positive breast cancer - operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1). Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anth Lees het volledige document